Moderna COVID-19 Vaccine by Joy Osiagwu
Even as the United States COVID-19 cases surpass 11million, hope is on the horizon with the latest news from Moderna, a COVID-19 vaccine candidate reporting 95% efficacy in the phase 3 trial of its jab.
The United States biotech firm in an interim investigation announced on Monday, November 16 that studies on 95 covid -19 infected patients who tried the vaccine revealed 95% potency.
The company says it is heading to the approval body for Food and Drugs Administration in the United States (USFDA) for its immediate consideration, given the current state of the pandemic in the United States.
The announcement is the second encouraging news from a COVID-19 vaccine candidate in November. Recall that Pfizer Inc. came up with exciting information about the efficacy of its COVID-19 vaccine about a week ago. Given this development, there is hope on the horizon for emergency use.
Reports show Moderna experimental vaccine seems to work well in seniors over the age of 55, even as it is said to be effective in young adults as well.
Canada has secured purchase orders for Moderna and Pfizer COVID-19 vaccines.